Edwin Moses

Chairman at Greywolf Therapeutics, NanoSyrinx, LabGenius, and Avantium NV

Speaker

Serial entrepreneur and value creator in European life science companies. As CEO built two businesses (Oxford Asymmetry International plc and Ablynx nv), led their successful IPOs on the LSE, EuroNext and NASDAQ and raised over €500M in equity and debt financing. Was responsible for developing the business plans and implementing them. Ran the sales process for each company generating values of £316M and €3.9Bn respectively. Expertise in high value service provision to the pharmaceutical industry and in drug discovery and development. At Ablynx, oversaw the whole process from discovery to approval and preparation for the launch of Cablivi™ - a product designed to treat an ultra-rare hematological disease. Primarily focussed on high growth businesses and change management. >30 years of Board level experience in more than 20 companies, mostly as Chairman. Currently mainly focussed on a small, high quality portfolio of Chairman/NED roles in both public and private life science companies with potentially breakthrough products/technologies, supporting the Board/management/company successfully undergo transformational changes. Been closely involved in raising more than €500M in equity and debt financing over the last 5 years. In December 2026, as Chair of Dark Blue Therapeutics, he was instrumental in the company’s sale to Amgen for up to $840M.